title: Pharmacogenomic testing and antithrombotic therapy: ready for prime time?
abstract: Pharmacogenomics is the study of an individual's interaction with a specific drug based upon the genetic make-up of the individual. Pharmacogenomic testing can be a powerful tool in testing a drug's potential efficacy and toxicity on an individual patient. For this tool to be used correctly, certain criteria have to be met. First and foremost is the strength of association between the genetic variation and the drug's interaction. The predictiveness of pharmacogenomics for the individual patient must be factored in as well. If these criteria are not met, requiring pharmacogenomic testing is at best a waste of money and in some cases can endanger the patient's life. Stent thrombosis is a serious and many times fatal outcome in a small minority of patients who have received drug-eluting stents. Here, we discuss a case in which the FDA issued a "boxed warning" about the use of the anti-clotting medication, clopidogrel, used to prevent stent thrombosis, the pharmacogenomic data available at the time the warning was issued, and the medical community's response to the FDA's warning. This article also discusses developments in the field of anti-clotting therapy since the FDA's warning.
authors.affiliation: Past President, American College of Cardiology (ACC); Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Holmes
keywords: Antiplatelet therapy; clopidogrel; pharmacogenomics; stent thrombosis
references.citation: PPAR Res. 2008;2008:374549
references.pmid: 18401448
references.citation: N Engl J Med. 2009 Jan 22;360(4):363-75
references.pmid: 19106083
references.citation: J Am Coll Cardiol. 2010 Jul 6;56(2):109-11
references.pmid: 20471193
references.citation: Lancet. 2010 Oct 16;376(9749):1312-9
references.pmid: 20801494
references.citation: JAMA. 2011 Nov 23;306(20):2221-8
references.pmid: 22088980
references.citation: Circulation. 2003 Jun 17;107(23):2908-13
references.pmid: 12796140
references.citation: N Engl J Med. 2009 Jan 22;360(4):354-62
references.pmid: 19106084
references.citation: JAMA. 2011 Dec 28;306(24):2704-14
references.pmid: 22203539
references.citation: Eur Heart J. 2011 Dec;32(23):2999-3054
references.pmid: 21873419
references.citation: Discov Med. 2011 Jun;11(61):551-61
references.pmid: 21712021
references.citation: Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11069-74
references.pmid: 16835302
references.citation: Circulation. 2011 Feb 1;123(4):e18-e209
references.pmid: 21160056
references.citation: JAMA. 2009 Aug 26;302(8):849-57
references.pmid: 19706858
references.citation: BMJ. 2011 Aug 04;343:d4588
references.pmid: 21816733
references.citation: Lancet. 2010 Oct 16;376(9749):1320-8
references.pmid: 20801498
references.citation: J Am Coll Cardiol. 2010 Jul 20;56(4):321-41
references.pmid: 20633831
references.citation: JAMA. 2011 Mar 16;305(11):1097-105
references.pmid: 21406646